Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy
Authors
Keywords
-
Journal
Cardiology in Review
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-26
DOI
10.1097/crd.0000000000000620
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential
- (2023) Shiavax J Rao et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
- (2023) Martin S. Maron et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Myosin Inhibitors
- (2023) Ajith Nair et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Multi-modality management of hypertrophic cardiomyopathy
- (2023) Shiavax J. Rao et al. Hospital practice (1995)
- Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3
- (2023) ANJALI T. OWENS et al. JOURNAL OF CARDIAC FAILURE
- Diagnosis and Evaluation of Hypertrophic Cardiomyopathy
- (2022) Barry J. Maron et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Management of Hypertrophic Cardiomyopathy
- (2022) Barry J. Maron et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
- (2022) Ahmad Masri et al. Journal of the American Heart Association
- Mavacamten: First Approval
- (2022) Susan J. Keam DRUGS
- A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants
- (2022) Fady I. Malik et al. JACC-Basic to Translational Science
- Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
- (2022) Masataka Kawana et al. Frontiers in Physiology
- Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
- (2022) Paul C. Cremer et al. Circulation-Cardiovascular Imaging
- Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
- (2021) Milind Y. Desai et al. AMERICAN HEART JOURNAL
- Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine
- (2021) Matthew J. Daniels et al. CIRCULATION
- Mavacamten
- (2021) Michael J. Capilupi et al. Cardiology in Review
- Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
- (2021) Chihyuan Chuang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
- (2020) Carolyn Y. Ho et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Iacopo Olivotto et al. LANCET
- Novel Pharmacotherapy in Hypertrophic Cardiomyopathy
- (2018) Gabriela Andries et al. Cardiology in Review
- Hypertrophic Cardiomyopathy: Mastering the Multiple Facets of a Complex Disease
- (2018) Srihari S. Naidu et al. CARDIOLOGY CLINICS
- Clinical Course and Management of Hypertrophic Cardiomyopathy
- (2018) Barry J. Maron NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility
- (2018) Ranganath Mamidi et al. Journal of the American Heart Association
- Historical Perspectives in the Evolution of Hypertrophic Cardiomyopathy
- (2018) Julio A. Panza et al. CARDIOLOGY CLINICS
- A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
- (2016) E. M. Green et al. SCIENCE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started